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Background: A recent clinical trial found that pharmacological blockade of V1b 28 
receptors reduces alcohol relapse in alcohol-dependent patients. SSR149415 is a selective V1b 29 
receptor antagonist that has potential for development as an alcohol dependency treatment. In 30 
this study, we investigated whether SSR149415 alone or in combination with the mu-opioid 31 
receptor [MOP-r] antagonist naltrexone (NTN) would alter excessive alcohol drinking in mice. 32 
Methods: Both sexes of C57BL/6J (B6) mice were subjected to a chronic intermittent access 33 
(IA) drinking paradigm (two-bottle choice, 24-h access every other day) for 3 weeks. Sucrose 34 
and saccharin drinking were used as controls for alcohol-specific drug effects. Neuronal 35 
proopiomelanocortin (POMC) enhancer (nPE) knockout mice with hypothalamic-specific loss of 36 
POMC (including beta-endorphin, the main endogenous ligand of MOP-r) were used as a 37 
genetic control for the effects of NTN. Results: Acute administration of SSR149415 (1-30 38 
mg/kg) reduced alcohol intake and preference in a dose-dependent manner in both male and 39 
female B6 mice after IA. To investigate potential synergistic effects between NTN and 40 
SSR149415, we tested six different combination doses of SSR149415 and NTN, and found that 41 
a combination of SSR149415 (3 mg/kg) and NTN (1 mg/kg) reduced alcohol intake profoundly 42 
at doses lower than the individual effective doses in both sexes of B6 mice. We confirmed the 43 
effect of SSR149415 on reducing alcohol intake in nPE-/- male mice, consistent with 44 
independent mechanisms by which SSR149415 and NTN decrease alcohol drinking. 45 
Conclusion: The combination of V1b antagonist SSR149415 with NTN at individual 46 
subthreshold doses shows potential in alcoholism treatment, possibly with less adverse effects. 47 
 48 
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Running title:
There is consistent evidence suggesting that increased arginine vasopressin (AVP) 53 
neuronal activity represents an important step in the neurobiology of stress-related behaviors in 54 
several rodent models [Griebel et al, 2002; Salome et al, 2006; Roper et al, 2011] and in 55 
humans [Katz et al, 2016; Ryan et al, 2017]. Chronic high levels of alcohol consumption activate 56 
endogenous AVP systems in neuronal structures related to alcohol dependence or compulsivity. 57 
Several studies have found that chronic alcohol exposure interfered with AVP gene expression 58 
or peptide levels in several brain stress responsive regions, like the bed nucleus of the stria 59 
terminalis, medial amygdala and hypothalamic paraventricular nucleus (PVN) in mice and rats 60 
[Ishizawa et al, 1990; Silva et al, 2002; Zhou et al, 2011]. In line with these findings, reduction of 61 
 V1b and naltrexone synergistically reduce alcohol drinkingINTRODUCTION 52 
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the number of AVP-immunoreactivity neurons and the AVP mRNA levels in the hypothalamus 62 
after chronic alcohol consumption has also been found in human brains [Harding et al, 1996]. 63 
These findings provide support for the importance of the AVP systems in the processes of 64 
alcohol consumption and addiction. 65 
Central AVP binds to two different G protein-coupled receptor subtypes: V1a and V1b, 66 
and both are highly expressed in the rat extended amygdala [Veinante and Freund-Mercier, 67 
1997]. Recently, activation of the V1b receptor system has been implicated in the negative 68 
reinforcing aspects of alcohol addiction. V1b protein levels are increased by alcohol withdrawal 69 
in the basolateral amygdala of alcohol-dependent rats [Edwards et al, 2012]. Pharmacological 70 
studies also support this notion: the systemically active, selective V1b antagonist SSR149415 71 
[Griebel et al, 2002] reduces voluntary alcohol consumption in alcohol “dependent” rats 72 
[Edwards et al, 2012] and Sardinian alcohol preferring rats with high anxiety-like behaviors 73 
[Colombo et al, 2006; Zhou et al, 2011]. Therefore, this enhanced AVP/V1b expression and/or 74 
activity may be involved in the homeostatic adaptations of the extended amygdala after chronic 75 
drug exposure and in the negative affective state during withdrawal. In a recent phase two, 76 
double-blind, placebo-controlled randomized trial, pharmacological blockade of V1b receptor 77 
reduces alcohol consumption and relapse in alcohol-dependent patients, especially those with 78 
high stress [Ryan et al, 2017].  79 
By targeting multiple neurotransmitter pathways implicated in different components of 80 
alcohol addiction, combination medications may have enhanced efficacy over the traditional 81 
single-medication approach. Given that naltrexone (NTN, mu-opioid receptor [MOP-r] 82 
antagonist) therapies have been used extensively in the treatment of alcoholism and V1b 83 
antagonists are in clinical trials, NTN and SSR149415 (MOP-r and V1b antagonisms, 84 
respectively) are ideal candidates for investigating the potential benefit of combined treatments. 85 
Therefore, we hypothesized that SSR149415 combined with NTN could synergistically decrease 86 
alcohol consumption in mice, and our study may provide new information about the medical 87 
potential of SSR149415 in the treatment of alcoholism. For this purpose, we first evaluated the 88 
pharmacological effect of SSR149415 alone in both male and female mice using both chronic 89 
intermittent access (IA) drinking and the drinking-in-the-dark (DID) models. In the IA model, 90 
which constitutes an appropriate animal model for studying excessive alcohol drinking [Hwa et 91 
al, 2011; Zhou et al, 2017a], the mice exposed to alcohol for 3 weeks developed high alcohol 92 
consumption. The sub-effective doses of NTN have been determined in our recent studies using 93 
the same IA paradigm [Zhou et al, 2017a, b]. Finally, we specifically tested the combinations of 94 
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SSR149415 and NTN using doses of each compound low enough that no effect on alcohol 95 
intake was found with either drug alone. 96 
Our mechanistic hypothesis is that the MOP-r activation by endogenous ligand beta-97 
endorphin has a different pathway driving excessive alcohol drinking from the AVP/V1b in the 98 
amygdala. In this study, we further investigated whether SSR149415 alters voluntary alcohol 99 
drinking in nPE knockout mice (targeted deletion of neuronal Pomc enhancers leading to the 100 
loss of central beta-endorphin and melanocortin peptide expression) [Lam et al, 2015], to 101 
explore potential neuronal mechanisms for synergistic effects of SSR149415 and NTN. 102 
METHODS AND MATERIALS 103 
1. Animals.  104 
1.1. Male and female adult C57BL/6J (B6) mice. Mice (8 weeks of age) were purchased from 105 
The Jackson Laboratory (Bar Harbor, ME, USA) and housed in a temperature-controlled room 106 
(21 ºC), with a 12-hour reverse light-dark cycle (lights off at 7:00 am) for a week prior to testing. 107 
During this week, mice were individually housed in ventilated cages fitted with steel lids and 108 
filter tops and given ad libitum access to food and water. Animal care and experimental 109 
procedures were conducted according to the Guide for the Care and Use of Laboratory Animals
 113 
 110 
(Institute of Laboratory Animal Resources Commission on Life Sciences 1996), and were 111 
approved by the Institutional Animal Care and Use Committee of the Rockefeller University. 112 
1.2. Pomc neuronal enhancer (nPE1 and nPE2) knockout mice. The present study used intact, 114 
male and female, single-housed mice with targeted deletion of the POMC neuronal enhancers 115 
nPE1 and nPE2 and insertion of a transcriptional blocking neo cassette in the enhancer locus 116 
(nPE-/-) [Bumaschny et al, 2012; Lam et al, 2015]. The gene mutations were generated by 117 
homologous recombination in 129S6/SvEvTac Taffy ES cells to produce the chimeric founder 118 
mice, followed by 7-10 generations of backcrossing onto the C57BL/6J strain for the mice used 119 
in these studies. Specifically, in these transgenic mice, simultaneous deletion of nPE1 and 120 
nPE2 and insertion of a neomycin selection cassette in the enhancer vicinity in the context of 121 
the intact Pomc pituitary enhancer region and proximal promoter abolishes Pomc expression in 122 
the arcuate nucleus, without altering Pomc expression in pituitary cells. nPE-/- mice had greater 123 
daily food intake at 8-9 weeks of age (5.2-5.3g in both males and females) than nPE+/+ mice 124 
(3.2-3.3g in both males and females). At the time the experiments started (age 8-10 weeks), 125 
nPE-/- mice had greater body weight (~ 40g and 35g in males and females, respectively) than 126 
nPE+/+ mice (~ 27g and 23g in males and females, respectively). 127 
Au
th
or
 M
an
us
cr
ip
t
ACER 17-3130 R2 
This article is protected by copyright. All rights reserved 
2. Materials. SSR149415 (a gift from Dr. G. Griebel, Sanofi Aventis, Montpellier, France) was 128 
suspended in 5% DMSO, 5% Cremophor and saline [Griebel et al, 2002]. Ethanol solutions 129 
(7.5%, 15% and 30% v/v) were prepared from 190 proof absolute ethyl alcohol (Pharmco-130 
AAPER, Brookfield, CT, USA) and dissolved in tap water. Sucrose and saccharin were 131 
purchased from Sigma-Aldrich Inc. (St. Louis, MO) and diluted in tap water. Naltrexone was 132 
purchased from Sigma-Aldrich Inc. and dissolved in physiological saline. 133 
3. Procedures. 134 
3.1. Chronic intermittent access (IA) excessive drinking. This model in B6 mice has been widely 135 
used by many laboratories [e.g., Hwa et al, 2011; Zhou et al, 2017b, c]. 136 
3.1A. The 3-week IA model. Mice had access to alcohol drinking in their home cages for 137 
3 weeks. Food and water were available at all times in this two-bottle choice paradigm with 138 
chronic alcohol exposure every other day. This IA protocol was described in detail in our earlier 139 
reports [Zhou et al, 2017b, c]. Briefly, starting at 10:00 am (3 hours after lights off), both water 140 
and alcohol (7.5%, 15% or 30%) solution sipper tubes were placed on the home cages. The 141 
tubes’ positions (left and right) on the cage were randomly set to avoid the development of side 142 
preference. The alcohol tubes were filled with fresh alcohol solution, placed on the cage for 24 143 
hours, and then replaced with the water tubes. After 4, 8 and 24 hours of alcohol access, 144 
alcohol and water intake values were recorded. These data were used to calculate the 145 
consumed alcohol intake (i.e., g ⁄ kg) and preference ratio for alcohol (i.e., alcohol intake ⁄ total 146 
fluid intake)
After 3 weeks of IA, male and female mice of vehicle and drug -treated groups had 148 
matched body weight and similar alcohol intake 24 hours before the test day. The compounds 149 
dissolved in vehicle were administered by an experimenter, blinded to the treatments assigned 150 
to the experimental groups. 151 
. 147 
3.1B. Acute administration in the 3-week IA model in B6 mice. On the test day, alcohol 152 
(7.5%, 15% or 30% concentrations) was presented 30 min after an injection of SSR149415 (1, 153 
3, 10, or 30 mg/kg, i.p.) or vehicle (5% DMSO and 5% Cremophor in saline), and then alcohol 154 
and water intake values were recorded. The SSR149415 doses chosen in the present 155 
experiments were based on our previous studies in rats [Zhou et al, 2011]. Similarly, the 156 
combined effects of SSR149415 (1 or 3 mg/kg) with sub-effective doses of NTN (0.5 or 1 157 
mg/kg) [Zhou et al, 2017b] were evaluated on alcohol drinking after the 3-week IA. On the test 158 
day, the mice received an i.p. injection of SSR149415 or vehicle followed by the second i.p. 159 
injection of NTN or saline 20 min later. Then alcohol was presented 10 min after NTN or vehicle 160 
and then alcohol and water intake values were recorded.  161 
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3.1C. Acute administration in the 3-week IA model in nPE mice
  168 
. The effects of 162 
SSR149415 were measured on alcohol drinking in two genotypes (nPE+/+ and nPE-/-) of each 163 
sex, and the sub-effective dose of SSR149415 chosen (3 mg/kg) was based on the data in B6 164 
mice in the above IA experiments. On the test day, 15% alcohol was presented 30 min after an 165 
injection of SSR149415 (i.p.) or vehicle (5% DMSO and 5% Cremophor in saline), and then 166 
alcohol and water intake values were recorded as described above. 167 
3.2. Chronic drinking-in-the-dark (DID). This model in B6 mice has been widely used by many 169 
laboratories [e.g., Rhodes et al, 2005; Sprow et al, 2016; Zhou et al 2017b, c]. Unlike the IA 170 
model above, mice were exposed to 15% alcohol every day in this one-bottle paradigm, with 171 
one recording per day (after 4 hours of alcohol access in the dark cycle).  172 
3.2A. The 3-week DID model.
These data were used to calculate alcohol intake (i.e., g ⁄ kg). After 3 weeks of DID, male 178 
and female mice of vehicle and drug -treated groups had matched body weight and similar 179 
alcohol intake 1 day before the test day. 180 
 This DID protocol was described in detail in our earlier 173 
reports [Zhou et al, 2017 b, c]. Briefly, at 3 hours after lights turned off (10:00 am), the water 174 
bottle was replaced with one alcohol (15%) tube, and left for 4 hours until the original water 175 
bottle was returned. After 4 hours of alcohol access, alcohol intake values were recorded every 176 
day. 177 
3.2B. Acute administration in the 3-week DID model in B6 mice.
 185 
 The SSR149415 doses 181 
(10 and 30 mg/kg) were based on the results of the above IA alcohol study. On the test day, 182 
15% alcohol was presented 30 min after an i.p. injection of SSR149415 or vehicle (5% DMSO 183 
and 5% Cremophor in saline). 184 
3.3. Sucrose (caloric reinforcer) and saccharin (non-caloric reinforcer) drinking. As the sucrose 186 
and saccharin drinking tests are sensitive to the function of brain reward systems, they are used 187 
to measure the expression of anhedonia after chronic alcohol drinking [e.g., Zhou et al 2017c]. 188 
Using the same doses, the specificity of the action of SSR149415 alone or combined with NTN 189 
on alcohol intake was further tested using sucrose or saccharin drinking behavior after acute 190 
administration of the combination following the 3-week IA. In the following experiments, 15% 191 
alcohol IA exposure was identical to those in the above experiment as described in section 3.1. 192 
After 3 weeks of IA, the alcohol tube was switched to sucrose or saccharin for 3 sessions, 193 
during which stable intake was observed after 6 days. The mice assigned to the vehicle or 194 
SSR149415 -treated groups in each sex had similar sucrose or saccharin intake 24 hours 195 
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before the test day. On the test day, sucrose (4%, 8% or 16%) and water intake values were 196 
recorded after 4, 8 and 24 hours of sucrose access. In parallel separate experiments, saccharin 197 
drinking (0.1%, 0.2% or 0.4%) was tested after 3 weeks of IA with an identical procedure.  198 
3.3A. Acute administration of SSR149415 (10 mg/kg) on sucrose or saccharin drinking 199 
after 3-week IA in B6 mice. An i.p. injection of SSR149415 (10 mg/kg) or vehicle (5% DMSO 200 
and 5% Cremophor in saline) was given 30 min before the sucrose or saccharin solutions were 201 
presented. Male and female mice were assigned to one of two treatment groups: vehicle or 202 
SSR149415. 203 
3.3B. Acute administration of SSR149415 (3 mg/kg) combined with NTN (1 mg/kg) on 204 
sucrose or saccharin drinking after 3-week IA in B6 mice. On the test day, the mice received the 205 
first i.p. injection of SSR149415 or vehicle followed by the second i.p. injection of NTN or saline 206 
20 min later. Male and female mice were assigned to one of two treatment groups: vehicle or 207 
SSR149415 + NTN. 208 
3.3C. Acute administration of SSR149415 (10 mg/kg) on sucrose or saccharin drinking 209 
in alcohol-naïve B6 mice.
 212 
 The procedures were identical to the above 3.3A and 3.3B 210 
experiments, except the mice were exposed to 4% sucrose or 0.1% saccharin only. 211 
4. Data analysis. Based on the between-groups approach (i.e. separate groups of mice for 213 
each dose) and levels of differences seen previously [Zhou et al, 2017a, b, c], we performed 214 
power analyses to determine the number of animals required to provide statistically significant 215 
results and predicted that these studies require 6-8 animals per group.  216 
There were 207 male and 211 female B6 mice analyzed in the present experiments.  In 217 
the experiments with SSR149415, NTN or their combinations, alcohol (or sucrose, saccharin) 218 
intake, water intake, total fluid and preference ratio differences in each sex across the different 219 
groups were analyzed using 2-way ANOVA with repeated measures for treatment (vehicle vs 220 
drug) and for time interval (0-4, 5-8 vs. 9-24h). For dose response analysis on SSR149415 221 
alone and SSR149415 + NTN combinations, group differences for alcohol intake and 222 
preference ratios at the 4-hour recording time were analyzed using 2-way ANOVA for 223 
treatments with different doses and for sex (male vs. female).  224 
There were 28 male and 24 female nPE mice (divided equally between nPE+/+ and 225 
nPE-/- genotypes) analyzed in the present experiments  In the nPE mouse experiment, group 226 
differences in alcohol intake, water intake and preference ratios in each sex were analyzed 227 
using 2-way ANOVA for genotype (nPE+/+ vs. nPE-/-) and treatments (vehicle vs. drug). 228 
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The 2-way ANOVAs were followed by Newman-Keuls post-hoc tests. The accepted level 229 
of significance for all tests was p < 0.05.  All statistical analyses were performed using Statistica 230 
(version 5.5, StatSoft Inc, Tulsa, OK). 231 
RESULTS 232 
1. Acute administration of SSR149415 alone 
1.1. Dose responses of SSR149415 on 15% alcohol intake and preference. The full-235 
dose response of acute SSR149415 administration (0, 1, 3, 10 and 30 mg/kg) in terms of 15% 236 
alcohol intake and preference at the 4-hour time point is presented in Fig 1. For alcohol intake 237 
(Fig 1A), there was a main effect of SSR149415 [2-way ANOVA, F (10,136) = 30, p < 238 
0.0000001], and post hoc analysis showed that (1) in comparison with the vehicle group, the 239 
SSR149415-treated mice had less intake than the vehicle-treated mice at both 10 and 30 mg/kg 240 
doses in both males and females [post-hoc test p < 0.01 for all]; and (2) the reductions at 10 241 
mg/kg were greater than those at 3 mg/kg [p < 0.05 for both sexes].  For preference ratio (Fig 242 
1B), there was a main effect of SSR149415 [2-way ANOVA, F (10,136) = 22, p < 0.0000001], 243 
and post hoc analysis showed that (1) in comparison with the vehicle group, the SSR149415-244 
treated mice had less preference than the vehicle-treated mice at both 10 and 30 mg/kg doses 245 
in both males and females [post-hoc test p < 0.01 for all]; and (2) the reductions at 30 mg/kg 246 
were greater than those at 3 mg/kg [p < 0.05 for both sexes].  247 
reduced alcohol, but not sucrose or 233 
saccharin, intake and preference after IA in both male and female B6 mice. 234 
1.2. Acute SSR149415 at 10 mg/kg reduced 15% alcohol intake and preference. Alcohol 248 
intake and preference ratio are presented in Fig 2 (male) and Fig 3 (female) after 4, 8 and 24 249 
hours of acute SSR149415 at 10 mg/kg. SSR149415 significantly reduced alcohol intake in 250 
males [2-way ANOVA, F (1, 13) = 6.7, p < 0.05] at 4 hours [post-hoc test p<0.005] (Fig 2A) and 251 
in females [2-way ANOVA, F (1, 12) = 6.2, p < 0.05] at 4 hours [post-hoc test p<0.001] (Fig 3A). 252 
This was associated with a compensatory increase in water intake in males and in females, 253 
resulting in virtually unchanged total fluid intake in both sexes (Table 1). At this dose, 254 
SSR149415 also significantly reduced preference ratio in males [2-way ANOVA, F (1, 13) = 5.4, 255 
p < 0.05] at 4 hours [post-hoc test p < 0.01] (Fig 2B) and in females [2-way ANOVA, F (1, 12) = 256 
15, p < 0.01] at 4 hours [post-hoc test p < 0.005] (Fig 3B). We did not observe any sex 257 
differences in the dose-response effects of SSR149415 alone in the above experiments, 258 
suggesting that the estrous cycle and associated hormones might not be important factors in the 259 
response to these treatments in females. 260 
1.3. Effects of acute SSR149415 on 7.5% or 30% alcohol intake and preference. After 261 
10 mg/kg SSR149415, there was an apparently slight decrease on either 7.5% (Table 2A) or 262 
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30% (Table 3A) alcohol intake in both male and female mice, although these could not research 263 
statistical significance.  No effects of 10 mg/kg SSR149415 on alcohol preference ratio were 264 
found in either males or females with either alcohol concentration (Tables 2A, 3A). 265 
1.4. No effects of acute SSR149415 on sucrose (caloric reinforcer) or saccharin (non-266 
caloric reinforcer) intake and preference. The specificity of the effect of SSR149415 on alcohol 267 
drinking was verified by testing the effects of 10 mg/kg SSR149415 on sucrose or saccharin 268 
intake. In these experiments, the chronic 15% alcohol IA procedures were identical to those in 269 
the above experiments. The mice assigned to the vehicle or SSR149415 -treated groups had 270 
similar sucrose or saccharin intake 24 hours before the test day. On the test day, no significant 271 
effect of 10 mg/kg SSR149415 on 4% sucrose (Table 4A) or 0.1% saccharin (Table 4C) 272 
drinking
Effects of SSR149415 on consumption of other concentrations of sucrose (8% or 16%) 275 
or saccharin (0.2% or 0.4%) were also tested in males and females (n = 4-5) and no significant 276 
differences were found. Similarly, there was no effect of acute SSR149415 at 10 mg/kg on 277 
sucrose or saccharin drinking in alcohol-naïve males and females (data not shown). 278 
 was found after 4 hours in either males (left) or females (right). There was no effect on 273 
sucrose or saccharin drinking observed after 8 or 24 hours (data not shown).  274 
2. Acute administration of SSR149415 combined with naltrexone (NTN) reduced alcohol, 279 
but not sucrose or saccharin, consumption after IA in both male and female B6 mice. 280 
2.1. Effect of acute administration of SSR149415 combined with NTN on 15% alcohol 281 
drinking. In both males and females, acute administration of SSR149415 (1 or 3 mg/kg) 282 
combined with NTN (1 mg/kg) reduced 15% alcohol intake and preference in a dose-dependent 283 
manner (data at the 4-hour time point are analyzed together and presented in Fig 1.  Combined 284 
with NTN at 0.5 mg/kg, acute administration of SSR149415 at two doses 
Combined with a higher dose of 1 mg/kg NTN, however, the SSR149415 at 1 mg/kg and 287 
3 mg/kg significantly reduced alcohol intake in male [post-hoc test p < 0.001 for both] and in 288 
female mice [post-hoc test p < 0.05 and p < 0.001, respectively] (Fig 1A), when compared with 289 
the vehicle group. The reductions at 3 mg/kg SSR149415 + 1 mg/kg NTN combination were 290 
greater than those at 1 mg/kg SSR149415 + 1 mg/kg NTN combination [p < 0.05 for both 291 
sexes]. Furthermore, this 3 mg/kg SSR149415 + 1 mg/kg NTN combination showed greater 292 
reductions of alcohol intake than 3 mg/kg SSR149415 alone in both males and females [post-293 
hoc test p < 0.001 for both] (Fig 1A). For preference ratio, only 3 mg/kg SSR149415 combined 294 
with 1 mg/kg NTN had significant reductions in both males and females [post-hoc test p < 0.01 295 
(1 or 3 mg/kg) did not 285 
reduce alcohol intake or preference in either males or females (Fig 1A, 1B). 286 
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for both] (Fig 1B). Similarly, the combination showed greater reductions of alcohol preference 296 
than 3 mg/kg SSR149415 alone in both males and females [post-hoc test p < 0.05] (Fig 1B). 297 
Figures 2C and 2D present 15% alcohol intake and preference ratio at all three time 298 
points (4, 8 and 24 hours) following one combination dose in males. Combined with 1 mg/kg 299 
NTN, 3 mg/kg SSR149415 significantly reduced alcohol intake [2-way ANOVA, F (1,13) = 30, p 300 
< 0.0001] between 0-4 and 9-24 hour intervals [post-hoc test p < 0.0001 and p < 0.05, 301 
respectively] (Fig 2C). This combination also significantly reduced preference ratio [2-way 302 
ANOVA, F (1,13) = 11, p < 0.01] between 0-4 and 9-24 hour intervals [post-hoc test p < 0.005 303 
and p < 0.05, respectively] (Fig 2D). There was no difference 24 hours after the test day (data 304 
not shown). Figures 3C and 3D present all three time points (4, 8 and 24 hours) in females. 305 
Combined with 1 mg/kg NTN, 3 mg/kg SSR149415 significantly reduced alcohol intake [2-way 306 
ANOVA, F (1,10) = 74, p<0.00001] between 0-4, 5-8 and 9-24 hour intervals [post-hoc test p < 307 
0.001, p < 0.001, and p < 0.05, respectively] (Fig 3C). This combination also significantly 308 
reduced preference ratio [2-way ANOVA, F (1,10) = 36, p < 0.0005] between 0-4, 5-8 and 9-24 309 
hour intervals [post-hoc test p < 0.005, p < 0.005 and p < 0.05, respectively] (Fig 3D
2.2. Effects of acute SSR149415 
). There 310 
was no difference 24 hours after the test day (data not shown). The combination dose had no 311 
effect on total fluid intake in either sex (Table 1). 312 
+ NTN on 7.5% or 30% alcohol intake and preference. 313 
There was an apparently slight decrease on either 7.5% (Table 2B) or 30% (Table 3B) alcohol 314 
intake in both males and females after 3 mg/kg SSR149415 + 1 mg/kg NTN, although these 315 
could not research statistical significance.  No effects on alcohol preference ratio were found in 316 
either males or females with either concentration. 317 
2.3. No effect of acute administration of SSR149415 combined with NTN on sucrose or 318 
saccharin drinking. The specificity of the effect of the SSR149415 + NTN combination on 319 
alcohol intake was ascertained by testing its effect on sucrose and saccharin drinking after IA. 320 
After 4 hours, no significant effect of 3 mg/kg SSR149415 + 1 mg/kg NTN (the most effective 321 
combination for reducing alcohol) on 4% sucrose or 0.1% saccharin drinking was found in either 322 
males (Table 4B, 4D) or females (Table 4B, 4D). Similarly, no significant effects of SSR149415 323 
+ NTN on other concentrations of sucrose (8% or 16%) or saccharin (0.2% or 0.4%) intake were 324 
observed in either males or females (n=4-5). There was no effect of SSR149415 + NTN
 327 
 on 325 
sucrose or saccharin drinking in alcohol-naïve males or females (data not shown). 326 
3. Acute administration of SSR149415 at a sub-effective dose reduced alcohol intake 328 
after 3-week IA in male, but not female, nPE-/- mice. 329 
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3.1. Acute administration of SSR149415 (3 mg/kg) reduced alcohol intake in nPE-/- 330 
males (Table 5A). For alcohol intake, 2-way ANOVA revealed significant effects of genotype [F 331 
(1, 24) = 80, p < 0.001] and SSR treatment [F (1, 24) = 5.4, p<0.05]. Post hoc analysis showed 332 
that: (1) between genotypes, nPE-/- males had less intake than nPE+/+ males [p < 0.01]; and 333 
(2) SSR treatment at 3 mg/kg further reduced intake in nPE-/- males [p < 0.05], but not nPE+/+ 334 
males. For water intake, 2-way ANOVA revealed a significant effect of genotype [F (1, 24) = 5.0, 335 
p < 0.05]. For alcohol preference, 2-way ANOVA revealed a significant effect of genotype [F (1, 336 
24) = 44, p < 0.001], and post hoc analysis showed that nPE-/- males had less preference than 337 
nPE+/+ males [p < 0.05]. 338 
3.2. Acute administration of SSR149415 (3 mg/kg) had no effect in nPE-/- females 339 
(Table 5B). For alcohol intake, 2-way ANOVA revealed significant effects of genotype [F (1, 20) 340 
= 38, p < 0.001], and post hoc analysis showed that nPE-/- females had less intake than nPE+/+ 341 
females [p < 0.01]. For water intake, 2-way ANOVA revealed a significant effect of genotype [F 342 
(1, 20) = 5.8, p < 0.05]. For alcohol preference, 2-way ANOVA revealed a significant effect of 343 
genotype [F (1, 20) = 59, p < 0.001], and post hoc analysis showed that nPE-/- females had less 344 
preference than nPE+/+ females [p < 0.05]. 345 
DISCUSSION 346 
Our first objective of the present study was to determine the dose responses of acute 347 
administration of SSR149415 in reducing alcohol consumption in mice after chronic IA 348 
excessive alcohol drinking.  At 10-30 mg/kg doses (but not 1-3 mg/kg), acute administration of 349 
SSR149415 significantly reduced alcohol intake in both males and females in the IA (Fig 1A), 350 
but not the DID (Table S1), model. Consistently, SSR149415 produced a reduction in alcohol 351 
preference in a dose-dependent (1-30 mg/kg) manner in both sexes (Fig 1B). It is unlikely that 352 
the effect of SSR149415 in reducing alcohol intake was secondary to a general suppression of 353 
consumption or appetitive (anhedonic effect) behaviors, since no tested doses of SSR149415 354 
affected sucrose or saccharin consumption or preference (Table 4). Of note, though there are 355 
sex differences in both AVP/V1b systems [Stewart et al, 2008] and alcohol drinking behavior 356 
[Becker and Koob 2016], it is intriguing that both male and female mice had similar dose 357 
responses to SSR149415 (Fig 1). The new finding is in line with results showing the reducing 358 
effect of SSR149415 on alcohol consumption in alcohol-dependent male rats [Edwards et al, 359 
2012] and alcohol-preferring male rats [Zhou et al, 2011]. To our knowledge, this is the first 360 
description of V1b antagonist SSR149415 on excessive alcohol drinking in both sexes 361 
compared side by side, suggesting that the blockade of V1b with SSR149415 may play a role in 362 
reducing alcohol drinking with no sex difference. 363 
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In a recent human study, acute administration of the selective V1b antagonist ABT-436 364 
(3 hours before alcohol drinking) did not have any effect on mean blood alcohol levels [Katz et 365 
al 2016]. Based on this pharmacokinetic result in humans, we do not expect any significant 366 
changes of alcohol blood levels after acute administration of SSR149415 in mice. 367 
To investigate whether alcohol drinking would alter endogenous AVP levels, many 368 
groups have measured AVP mRNA levels in both the PVN and amygdala of rats or mice after 369 
chronic alcohol exposure, and found that chronic alcohol drinking is associated with decreases 370 
in AVP mRNA levels in the PVN and the extend amygdala in rodents [e.g., Gulya et al, 1991; 371 
Silva et al, 2002; Zhou et al, 2011].  In parallel with mRNA changes, prolonged alcohol 372 
consumption is also associated with decreases in the levels of AVP-immunoreactivity in the 373 
mouse PVN and bed nucleus of the stria terminalis [Gulya et al, 1991]. In the hypothalamus of 374 
human post-mortem brains of alcoholic subjects, reduction of the number of AVP-375 
immunoreactivity neurons and the AVP mRNA levels is also reported [Harding et al, 1996]. As 376 
AVP neurons in the PVN are distributed in both parvocellular and magnocellular divisions, and 377 
have potentially differential responses to stress, it is not clear that the altered plasma AVP levels 378 
in human studies are correlated to the AVP in parvocellular or magnocellular cells in response 379 
to alcohol withdrawal stress [Eisenhofer et al, 1985; Trabert et al, 1992]. However, recent 380 
studies suggest that activation of the V1b receptor could play important roles in acute drug 381 
withdrawal from long-term drug exposure [Zhou et al, 2008; Edwards et al, 2012; Qi et al, 2015]. 382 
Importantly, the blockade of V1b activity in the amygdala reduces the negative reinforcing action 383 
of alcohol consumption [Edwards et al, 2012]. Alternatively, the above new data suggest that 384 
the V1b expression, binding and function, as well as the downstream effects of V1b receptor 385 
signaling (rather than the AVP itself) can be more involved in the behavioral effects of alcohol 386 
drinking. Unfortunately, there is very limited research on V1b with alcohol or other drugs of 387 
abuse. 388 
Our main objective was to investigate potential synergistic effects between NTN and 389 
SSR149415. In both preclinical and clinical studies, numerous pharmacological experiments 390 
provide consistent evidence that NTN, as a selective MOP-r antagonist, decreases alcohol 391 
consumption, reward, craving and relapse in many rodent models and human studies. 392 
SSR149415 is highly selective for the V1b receptor (60- to 800-fold more than for the V1a 393 
receptor), and displays anxiolytic, antidepressant and anti-alcohol properties in rodents [Griebel 394 
et al, 2002;  Salome et al, 2006; Zhou et al, 2011; Edwards et al, 2012]. An investigation into the 395 
combination of these two compounds (NTN and SSR149415) could be particularly intriguing, 396 
given that these drugs have distinctly different mechanisms of actions. Due to its high selectivity 397 
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for the MOP-r and the low doses used in our studies, we predicted that NTN’s activity at the 398 
MOP-r would not interfere with SSR149415’s effect on the V1b. In fact, our results 399 
demonstrated that the combination of NTN and SSR149415 could have a synergistic, rather 400 
than additive, effect of the individual drugs on reducing alcohol intake and preference. 401 
Indications that the SSR149415 + NTN combination is more effective and potentially more 402 
beneficial in reducing alcohol intake than either drug alone include: (a) the effects of these 403 
combined, low-dose administrations of SSR149415 + NTN on alcohol drinking were 3 times 404 
greater than those of either drug alone (Fig 1); and (b) the combination showed a long-lasting 405 
effect after acute administration in both male (Fig 2) and female (Fig 3) mice. Finally, the 406 
specific effect of the combination on alcohol consumption was supported by the lack of any 407 
effect on sucrose or saccharin consumption (Table 4). 408 
As the effectiveness of this SSR149415 + NTN combination could involve multiple 409 
neuro-pharmacological mechanisms (at least V1b and MOP-r), we hypothesized that this 410 
combination would be synergistic in reducing alcohol drinking. Indeed, neurobiological studies 411 
have found supportive observations, given the multiple actions of alcohol in the CNS and that 412 
both the MOP-r and V1b systems are profoundly altered by chronic alcohol exposure [Koob and 413 
Kreek 2007; Koob 2008]. NTN's actions are mediated through the blockade of MOP-r in the 414 
mesolimbic circuitries that may reduce the alcohol rewarding effect (positive reinforcement). In 415 
contrast, neuroanatomical distribution of V1b receptor is prominent in the stress responsive 416 
regions, like the amygdala and hypothalamus [Hernando et al, 2001; Koob 2008], and the 417 
AVP/V1b system in the extended amygdala could be a critical component contributing to the 418 
negative reinforcing effects during alcohol withdrawal. Indeed, activation of the AVP/V1b system 419 
in the amygdala has been found in drug withdrawal from several weeks of drug exposure, and 420 
the blockade of V1b activity in the amygdala reduces the negative reinforcing action of alcohol 421 
consumption [Edwards et al, 2012]. Systemic administration of V1b antagonists blocks the 422 
stress- and drug priming- triggered heroin seeking [Zhou et al, 2008] and prevents the dysphoria 423 
induced by nicotine withdrawal [Qi et al, 2015], as well as nicotine-induced locomotor 424 
sensitization [Goutier et al, 2016]. In humans, there were abnormal levels of serum and urine 425 
AVP during alcohol withdrawal, particularly when symptoms are severe [Eisenhofer et al, 1985; 426 
Trabert et al, 1992]. Therefore, by targeting MOP-r and V1b pathways implicated in both 427 
“positive” and “negative” components of alcohol addiction, the combination of NTN and 428 
SSR149415 is likely to have enhanced efficacy over the single-pathway approaches.  In 429 
humans, NTN activates the hypothalamic-pituitary-adrenal (HPA) axis, and reduces alcohol 430 
drinking and craving [O’Malley et al, 2002]. As V1b activation in the anterior pituitary is also 431 
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involved in HPA regulation in humans [e.g., Katz et al, 2016], the combination of SSR149415 432 
and NTN could synergistically modulate the HPA activity. Also, the corticotropin-releasing factor 433 
(CRF) and noradrenergic systems, the two known key stress mediators that are involved in 434 
stress and anxiety responses, probably interact with AVP systems to regulate alcohol drinking 435 
as demonstrated before [e.g., Simms et al, 2014; Tunstall et al, 2017]. 436 
Of note, the present study showed a relatively long duration (at least 24 hours) of the 437 
effect of SSR149415 + NTN combination on alcohol drinking behavior (especially the females) 438 
(Figs 2 and 3), which is unlikely due to SSR149415 metabolic stability and bioavailability in vivo 439 
(half-life is <1 h) [Oost et al, 2011]. In contrast, SSR149415 alone significantly reduced alcohol 440 
drinking at 4 hours with a similar profile to NTN alone (half-life is approximately 4 h), a reference 441 
compound in reducing alcohol drinking in our mouse model. Though the potential mechanisms 442 
are unknown, the development of new SSR149415 + NTN combination with improved 443 
pharmacokinetics may have the potential to yield a useful therapy for the treatment of 444 
alcoholism. 445 
In contrast to mice in the intermittent 24-hour access IA paradigm [Hwa et al, 2011], 446 
which had excessive daily alcohol intake with 15% alcohol (~18 g/kg in males and ~23 g/kg in 447 
females, respectively), mice in the limited-access DID paradigm [Rhodes et al, 2005] had 448 
modest daily intake with 15% alcohol (~5 g/kg in males and females). For this reason, we 449 
purposely compared the effects of SSR149415 on the IA with DID, and found that single acute 450 
SSR149415 administration at 10 mg/kg reduced alcohol drinking at 4 hours after IA (Fig 2, 3), 451 
with no effect after DID (Table S1). When tested in other alcohol concentrations in the IA model, 452 
we observed that SSR149415 alone or combined with NTN had effect on high levels of daily 453 
alcohol intake with 15% alcohol, without a significant reduction on relatively low levels of daily 454 
alcohol intake with 7.5% alcohol (~10 g/kg in males and ~20 g/kg in females, respectively) 455 
[Zhou et al, 2017a, b] (Table 2), consistent with the above notion. However, the results (Table 456 
3) that SSR149415 alone or combined with NTN showed a “selective” effect on 15% alcohol, 457 
but not on 30% alcohol with high daily alcohol intake (~23 g/kg in males and ~34 g/kg in 458 
females, respectively) [Zhou et al, 2017a, b] was unexpected. Further study to elucidate these 459 
findings is warranted. 460 
Using the IA model, our recent study found that nPE-/- mice of both sexes had lowered 461 
intake and preference for alcohol, suggesting a reduced rewarding effect of alcohol when 462 
central beta-endorphin, the main peptide ligand of MOP-r, is reduced [Zhou et al, 2017a]. 463 
Therefore, we purposely investigated whether the blockade of V1b receptors could further affect 464 
alcohol drinking in nPE knockout mice lacking central beta-endorphin.  We found that nPE-/- 465 
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males displayed a significant reduction in alcohol intake after acute administration of 3 mg/kg 466 
SSR149415 (Table 5), indicating a sensitized effect of V1b antagonist SSR149415 after the 467 
central POMC/beta-endorphin deletion. This also suggests that the presence of SSR149415 468 
effects in nPE-/- males was due to an independent and different mechanism from that of NTN, 469 
as discussed above.  In contrast, we observed no effect of acute treatment with 3 mg/kg 470 
SSR149415 on alcohol drinking in the IA paradigm in nPE-/- females, though the same 471 
SSR149415 treatment significantly reduced alcohol drinking in nPE-/- males. As the decreased 472 
alcohol intake in nPE-/- mice was more notable in females, the lack of significant effect of 473 
SSR149415 in nPE-/- females may be a floor effect due to their much lowered basal alcohol 474 
intake. 475 
Together, the present study in a mouse excessive alcohol drinking model suggests that 476 
the combination of SSR149415 with NTN may be more efficacious in treating alcoholism than 477 
NTN alone. There are several precedents to test the combinations of NTN with other 478 
compounds, like acamprosate [Heyser et al, 2003], prazosin [Froehlich et al, 2013] and Mesyl 479 
Sal B [Zhou et al, 2017b]. In comparison with those combinations, this new combination with 480 
SSR149415 showed a long-lasting synergistic effect on reducing alcohol consumption, although 481 
this could be attributed to different animal models used in different laboratories. Excessive 482 
alcohol drinking is widely considered a hallmark of the transition from alcohol abuse to addiction 483 
in humans [Koob 2008]. Together, consistent with several recent studies on alcohol drinking in 484 
rats and in humans, our findings have shown further promising in vivo data indicating that 485 
subthreshold doses of  a V1b antagonist in combination with NTN, may offer novel strategies to 486 
treat alcoholism, and possibly with less adverse effects. 487 
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Figure 1 Dose responses of acute administration of SSR149415 (SSR, 0, 1, 3, 10 or 30 601 
mg/kg) alone or combined with naltrexone (NTN, 0, 0.5 or 1 mg/kg) on reducing 15% alcohol 602 
intake (A) and alcohol preference (B) after 3-week intermittent access drinking in both male and 603 
female B6 mice. Data were collected at the 4-hour time point on the baseline and testing day 604 
(24 hours later) and are expressed as a percentage of baseline alcohol intake to account for the 605 
differences in baseline that contribute to variation between experiments. n=6-8. *p<0.05 or 606 
**p<0.01 vs. control (both SSR 
Figure 2 Effects of acute administration of SSR149415 (SSR, 10 mg/kg) alone or 3 609 
mg/kg SSR combined with naltrexone (NTN, 1 mg/kg) on 15% alcohol intake and preference 610 
ratio after 3-week intermittent access drinking in male B6 mice. [A, B] SSR alone: (1) Control 611 
group (n=7): males received one vehicle injection (5% DMSO and 5% Cremophor in saline for 612 
SSR149415 control, i.p.) before the drinking test; and (2) SSR149415 group (n=8): males 613 
received one SSR149415 injection (10 mg/kg, i.p.) before the drinking test; [C, D] SSR + NTN: 614 
(1) Control group (n=8): males received one vehicle (5% DMSO and 5% Cremophor in saline for 615 
SSR149415 control, i.p.) followed by saline (for NTN control, i.p.) before the drinking test; and 616 
(2) SSR149415 + NTN group (n=7): males received one SSR149415 injection (3 mg/kg, i.p.) 617 
followed by one NTN injection (1 mg/kg, i.p.) before the drinking test. On the test day, alcohol 618 
(15%) intake values were recorded after 4, 8 and 24 hours of alcohol access. 
and NTN at 0 mg/kg); #p<0.05 or ## p<0.01 between treatment 607 
groups. 608 
Figure 3 Effects of acute administration of SSR149415 (SSR, 10 mg/kg) alone or 3 621 
mg/kg SSR combined with naltrexone (NTN, 1 mg/kg) on 15% alcohol intake and preference 622 
ratio after 3-week intermittent access drinking in female B6 mice. [A, B] SSR alone: (1) Control 623 
group (n=7): females received one vehicle injection (5% DMSO and 5% Cremophor in saline for 624 
SSR149415 control, i.p.) before the drinking test; and (2) SSR149415 group: females (n=7) 625 
received one SSR149415 injection (10 mg/kg, i.p.) before the drinking test. [C, D] SSR + NTN: 626 
(1) Control group (n=6): females received one vehicle (5% DMSO and 5% Cremophor in saline 627 
for SSR149415 control, i.p.) followed by saline (for NTN control, i.p.) before the drinking test; 628 
and (2) SSR149415 + NTN group (n=6): females received one SSR149415 injection (3 mg/kg, 629 
i.p.) followed by one NTN injection (1 mg/kg, i.p.) before the drinking test. On the test day, 630 
alcohol (15%) intake values were recorded after 4, 8 and 24 hours of alcohol access. 
* p<0.05, 619 
**p<0.01, ***p<0.005 and ****p<0.001 vs. control at the same time point. 620 
 
* p<0.05, 631 
**p<0.01, ***p<0.005 and ****p<0.001 vs. control at the same time point. 632 
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Table 1 Effects of acute administration of SSR149415 (SSR, 10 mg/kg) (A) and its combination 
with naltrexone (NTN) (3 mg/kg SSR + 1 mg/kg NTN) (B) on total fluid intake in male and female 
B6 mice after 3-week intermittent access drinking. 
 A. 
Total fluid male (n=7-8) female (n=7) 
intake, ml Vehicle 10 mg/kg SSR  Vehicle  10 mg/kg SSR  
0-4h  1.60 ± 0.09 1.58 ± 0.20 1.88 ± 0.11 1.69 ± 0.21 
5-8h  1.04 ± 0.10 1.18 ± 0.28 1.72 ± 0.22 1.65 ± 0.30 
9-24h  2.84 ± 0.32 2.78 ± 0.37 3.20 ± 0.44  3.11 ± 0.55 
 B. 
Total fluid male (n=7-8) female (n=6) 
intake, ml Vehicle 3 mg/kg SSR  
+ 1mg/kg NTN 
Vehicle  3 mg/kg SSR 
+ 1mg/kg NTN 
0-4h 1.55 ± 0.11  1.49 ± 0.29  1.68 ± 0.23 1.79 ± 0.29 
5-8h 1.10 ± 0.30 1.19 ± 0.45 1.59 ± 0.20  1.81 ± 0.53 
9-24h  3.05 ± 0.51 2.94 ± 0.35 3.17 ± 0.61  3.23 ± 0.33 
 
 
 
Table 2 Effects of acute administration of SSR149415 (SSR, 10 mg/kg) (A) and its combination 
with naltrexone (NTN) (3 mg/kg SSR + 1 mg/kg NTN) (B) on 7.5% alcohol intake and preference 
ratio after 3-week intermittent access drinking at 4 hours in male and female B6 mice. 
A male (n=6) female (n=6) 
Treatment Vehicle 10 mg/kg SSR Vehicle 10 mg/kg SSR 
Alcohol intake (g/kg/4h) 4.12 ± 0.30 3.52 ± 0.33 5.51 ± 0.51 3.76 ± 0.39 
Preference ratio 0.90 ± 0.02 0.89 ± 0.01 0.91 ± 0.02 0.85 ± 0.05 
 
B male (n=6) female (n=7) 
Treatment Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
Alcohol intake (g/kg/4h) 3.75 ± 0.31 3.27 ± 0.20 5.14 ± 0.52 3.88 ± 1.02 
Preference ratio 0.94 ± 0.01 0.88 ± 0.07 0.92 ± 0.01 0.86 ± 0.10 
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Table 3 Effects of acute administration of SSR149415 (SSR, 10 mg/kg) (A) and its combination 
with naltrexone (NTN) (3 mg/kg SSR + 1 mg/kg NTN) (B) on 30% alcohol intake and preference 
ratio after 3-week intermittent access drinking at 4 hours in male and female B6 mice. 
A male (n=7) female (n=7-8) 
Treatment Vehicle 10 mg/kg SSR Vehicle 10 mg/kg SSR 
Alcohol intake (g/kg/4h) 5.04 ± 0.32 4.73 ± 0.39 7.51 ± 0.82 6.57 ± 0.91 
Preference ratio 0.50 ± 0.05 0.49 ± 0.04 0.64 ± 0.04 0.67 ± 0.05 
 
B male (n=6) female (n=7-8) 
Treatment Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
Alcohol intake (g/kg/4h) 5.38 ± 0.97 5.07 ± 0.50 5.91 ± 1.01 4.89 ± 0.81 
Preference ratio 0.53 ± 0.04 0.55 ± 0.04 0.51 ± 0.06 0.53 ± 0.07 
 
 
 
Table 4 Effects of acute administration of SSR149415 (SSR, 10 mg/kg) (A) and its combination 
with naltrexone (NTN) (3 mg/kg SSR + 1 mg/kg NTN) (B) on 4% sucrose (A and B) or 0.1% 
saccharin (C and D) intake and their preference ratio at 4 hours in male and female B6 mice. 
A male (n=6) female (n=6) 
Treatment Vehicle 10 mg/kg SSR Vehicle 10 mg/kg SSR 
4% Sucrose (g/kg/4h) 8.01 ± 0.82 9.15 ± 1.08 8.51 ± 1.15 10.7 ± 1.05 
Preference ratio 0.95 ± 0.02 0.97 ± 0.03 0.96 ± 0.01 0.97 ± 0.02 
 
B male (n=6) female (n=8-10) 
Treatment Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
4% Sucrose (g/kg/4h) 7.59 ± 1.37 8.17 ± 1.01 8.14 ± 0.72 8.88 ± 1.02 
Preference ratio 0.91 ± 0.05 0.97 ± 0.01 0.96 ± 0.06 0.95 ± 0.10 
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C male (n=6-7) female (n=6) 
Treatment Vehicle 10 mg/kg SSR Vehicle 10 mg/kg SSR 
0.1% Saccharin (g/kg/4h) 0.12 ± 0.03 0.13 ± 0.01 0.15 ± 0.02 0.16 ± 0.03 
Preference ratio 0.94 ± 0.03 0.98 ± 0.02 0.96 ± 0.02 0.98 ± 0.02 
 
D male (n=6) female (n=6) 
Treatment Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
Vehicle 
+ Saline 
3 mg/kg SSR 
+ 1 mg/kg NTN 
0.1% Saccharin (g/kg/4h) 0.18 ± 0.01 0.20 ± 0.02 0.19 ± 0.07 0.18 ± 0.02 
Preference ratio 0.96 ± 0.01 0.97 ± 0.01 0.96 ± 0.01 0.96 ± 0.01 
 
 
Table 5 Genotype differences in the effects of acute SSR149415 (SSR, 3 mg/kg) on 15% 
alcohol intake and preference ratio after 3-week intermittent access drinking at 4 hours in male 
(A) and female (B) nPE mice. Mice of each sex were assigned to one of four treatment groups: 
(1) nPE+/+ with vehicle (5% DMSO and 5% Cremophor in saline) as control; (2) nPE+/+ with 3 
mg/kg SSR in vehicle; (3) nPE-/- with vehicle as control; and (4) nPE-/- with 3 mg/kg SSR. On 
the test day, 15% alcohol was presented 30 min after a single i.p. injection of SSR or vehicle, 
and then alcohol and water intake values were recorded after 4, 8 and 24 hours of alcohol 
access.  Data are presented after 4 hours of alcohol access. Genotype difference: *p<0.05 or ** 
p<0.01 vs. nPE+/+ mice after the same treatment; SSR treatment difference:  #p<0.05 vs. 
vehicle control in the same genotype. 
Genotype 
A. Males (n=7) 
nPE +/+ nPE -/- 
Treatment vehicle 3 mg/kg SSR vehicle 3 mg/kg SSR 
Intake, g/kg 5.4 ± 0.50 5.1 ± 0.47 2.8 ± 0.27 ** 1.5 ± 0.28 # 
Water, ml 0.32 ± 0.11 0.30 ± 0.10 0.51 ± 0.14 0.66 ± 0.16 
Preference 0.77 ± 0.06 0.70 ± 0.05 0.54 ± 0.07 * 0.46 ± 0.03 
 
 B. Females (n=6) 
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Genotype nPE  +/+ nPE -/- 
Treatment vehicle 3 mg/kg SSR vehicle 3 mg/kg SSR 
Intake 6.6 ± 0.49  6.1 ± 0.38  1.5 ± 0.39 ** 1.4 ± 0.42  
Water, ml 0.25 ± 0.09 0.24 ± 0.10 0.51 ± 0.14 0.50 ± 0.11 
Preference  0.85 ± 0.06  0.82 ± 0.08  0.44 ± 0.10 **  0.40 ± 0.08  
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